REITHERA

🚀𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐍𝐞𝐰𝐬 𝐢𝐧 𝐆𝐞𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲! 🚀 We're thrilled to share that 𝐑𝐞𝐢𝐓𝐡𝐞𝐫𝐚 has successfully manufactured and released the Drug Substance and Drug Product for AAVantgarde Bio groundbreaking 𝐋𝐔𝐂𝐄-𝟏 𝐭𝐫𝐢𝐚𝐥, which aims to treat Usher Syndrome Type 1B through the innovative AAVB-081 gene therapy. This First-in-Human trial represents a significant advancement in gene therapy, utilizing a proprietary dual-AAV platform to deliver the large MYO7A gene directly to patients suffering from retinitis pigmentosa. With approximately 20,000 individuals affected in the U.S. and E.U., this research holds the potential to transform lives. We are proud to collaborate with AAVantgarde, a spin-off of Telethon Institute for Genetics and Medicine (TIGEM) on this project. Our team’s expertise in GMP manufacturing and quality control has been essential in bringing this innovative treatment closer to those in need. As we push the boundaries of biotechnology, we remain committed to advancing medical science for the benefit of patients around the world. Congratulations to AAVantgarde Bio on dosing the first subject in the LUCE-1 trial! Let’s continue to pave the way for groundbreaking advancements in healthcare together. 💡 Read our Press Release at: https://lnkd.in/dtPvdiYS #GeneTherapy #UsherSyndrome #Biotechnology #Collaboration #Innovation #Healthcare #ReiThera #AAVantgarde

🌍✨ 𝗥𝗲𝗳𝗹𝗲𝗰𝘁𝗶𝗻𝗴 𝗼𝗻 𝗮𝗻 𝗶𝗻𝘀𝗽𝗶𝗿𝗶𝗻𝗴 𝗘𝗦𝗚𝗖𝗧 𝟮𝟬𝟮𝟰 𝗲𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲! ✨🌍 As we return from an incredible week at #ESGCT2024, our hearts and minds are brimming with gratitude and excitement. Events like these remind us why we’re here—to connect, to share, and to innovate alongside some of the most passionate, driven professionals in our field. One of the true highlights? 𝗧𝗵𝗲 𝗵𝘂𝗺𝗮𝗻 𝘀𝗶𝗱𝗲 𝗼𝗳 𝗘𝗦𝗚𝗖𝗧. The moments spent in deep discussion, laughing over shared challenges, exchanging fresh perspectives, and sparking ideas for a healthier, safer world. Each handshake and conversation was a reminder of the power of collaboration and how, together, we push the boundaries of science to create meaningful impact. To everyone we had the pleasure of meeting, thank you for your insights, your stories, and your vision. Your dedication fuels us at ReiThera, reaffirming our mission to bring transformative therapies to life. 🌱💡 Looking forward to future collaborations and continuing the conversations we began here. 𝗨𝗻𝘁𝗶𝗹 𝗻𝗲𝘅𝘁 𝘁𝗶𝗺𝗲, 𝗘𝗦𝗚𝗖𝗧! #ESGCT #ReiThera #ConnectingForHealth #InnovationThroughCollaboration #ThankYou

🌟 𝐃𝐚𝐲 𝟑 𝐚𝐭 𝐄𝐒𝐆𝐂𝐓: 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧𝐬 𝐚𝐧𝐝 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧𝐬 𝐢𝐧 𝐀𝐀𝐕 𝐏𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧🌟 Today at #ESGCT2023, we were thrilled to present alongside our amazing collaborators at Virica Biotech! Here’s what we highlighted: 🔹 𝐕𝐢𝐫𝐢𝐜𝐚’𝐬 𝐕𝐢𝐫𝐚𝐥 𝐒𝐞𝐧𝐬𝐢𝐭𝐢𝐳𝐞𝐫 (𝐕𝐒𝐄™) 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 – a game-changer in the field, enhancing viral yields by dialing down cellular defenses, ensuring optimal production for AAV vectors. 🔹 𝐑𝐞𝐢𝐓𝐡𝐞𝐫𝐚’𝐬 𝐩𝐫𝐨𝐩𝐫𝐢𝐞𝐭𝐚𝐫𝐲 𝐜𝐥𝐨𝐧𝐚𝐥 𝐜𝐞𝐥𝐥 𝐥𝐢𝐧𝐞, 𝐑𝐞𝐢𝐂𝐞𝐥𝐥–𝐀𝐀𝐕𝐱 – meticulously selected for high-density suspension growth, perfectly complementing our work with Virica’s VSE™ platform. We showcased the powerful results from combining ReiCell–AAVx with Virica’s cell enhancers, and the feedback was overwhelmingly positive. Attendees were engaged, the turnout was fantastic, and the productive conversations continued well beyond the session! ReiThera is having a truly exceptional experience at 𝐄𝐒𝐆𝐂𝐓 – thrilled to be among such passionate minds and excited about the future of viral vector production. Looking forward to more insights today! 🚀 #GeneTherapy #AAV #Biotech #Collaboration #ReiThera

🚀 𝗗𝗮𝘆 𝟮 𝗮𝘁 𝗘𝗦𝗚𝗖𝗧 has been another fantastic day for the ReiThera team! We were thrilled to see Angelo Raggioli, PhD and Michela Gentile, PhD deliver engaging oral presentations that sparked great interest: 🎤 Angelo highlighted the potential of our GRAd vaccine platform for addressing global health challenges like COVID-19 and HIV. 🎤 Michela shared her innovative work on optimizing the two-plasmid system for AAV production by using our 𝗥𝗲𝗶𝗖𝗲𝗹𝗹-𝗔𝗔𝗩 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺, pushing the boundaries of gene therapy. Their presentations truly underscored the cutting-edge science we’re advancing at ReiThera. If you’re attending ESGCT, don’t miss the chance to stop by our booth B14/16! Come grab a coffee, take home one of our adorable plush toys, and enjoy some Nutella while we chat about the future of gene and cell therapy. 🍫☕️ #ESGCT2024 #ReiThera #VaccineInnovation #GeneTherapy #Biotech #GlobalHealth #Networking #NutellaTime

Innovation meets efficiency in AAV production! 📣 Join Virica Biotech and REITHERA for a collaborative presentation on Thursday, the 24th at 11 AM at Booth B14/16 at #ESGCT2024 #AAV #GeneTherapy #Biotech #LifeSciences #ViricaBiotech #Innovation

🌍 𝗗𝗮𝘆 𝟭 𝗮𝘁 𝗘𝗦𝗚𝗖𝗧 𝗵𝗮𝘀 𝗯𝗲𝗲𝗻 𝗮𝗻 𝗶𝗻𝘀𝗽𝗶𝗿𝗶𝗻𝗴 𝗮𝗻𝗱 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝘃𝗲 𝘀𝘁𝗮𝗿𝘁 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗥𝗲𝗶𝗧𝗵𝗲𝗿𝗮 𝘁𝗲𝗮𝗺! We had the privilege of meeting with several key leaders and innovators in the gene and cell therapy field, exchanging insights and discussing exciting future collaborations. From our meetings yesterday, it's clear that the future of advanced therapies is bright, and we are committed to making impactful contributions to global health. 𝗦𝘁𝗮𝘆 𝘁𝘂𝗻𝗲𝗱 𝗳𝗼𝗿 𝗺𝗼𝗿𝗲 𝘂𝗽𝗱𝗮𝘁𝗲𝘀 𝗳𝗿𝗼𝗺 𝗘𝗦𝗚𝗖𝗧, 𝗮𝗻𝗱 𝗰𝗵𝗲𝗰𝗸 𝗼𝘂𝘁 𝘁𝗵𝗲 𝗽𝗶𝗰𝘁𝘂𝗿𝗲𝘀 𝗳𝗿𝗼𝗺 𝘆𝗲𝘀𝘁𝗲𝗿𝗱𝗮𝘆’𝘀 𝗺𝗲𝗲𝘁𝗶𝗻𝗴𝘀! 👇 #ESGCT2024 #ReiThera #GeneTherapy #CellTherapy #BiotechInnovation #Partnerships #GlobalHealth

🎉 𝗪𝗲 𝗮𝗿𝗲 𝗵𝗲𝗿𝗲 𝗮𝘁 𝗘𝗦𝗚𝗖𝗧 𝟮𝟬𝟮𝟰! 🎉 The wait is over, and we’re excited to connect with you at the ESGCT 2024 conference. Visit us at 𝗕𝗼𝗼𝘁𝗵 𝗕𝟭𝟰/𝟭𝟲 for direct discussions with our team about the latest advancements in gene and cell therapy! 🔹 Stefano Colloca, CEO of ReiThera 🔹 Claudio Panzarella, Head of Business Development 🔹 Angelo Raggioli, Head of Technology Development And many more! Come by to explore collaboration opportunities and learn more about how ReiThera is shaping the future of biotech. We’re looking forward to meeting you in person! 📍 Booth B14/16 📅 October 22-25 #ESGCT2024 #ReiThera #GeneTherapy #CellTherapy #Biotech #Innovation #BusinessDevelopment

🎉 𝗪𝗲'𝗿𝗲 𝗵𝗲𝗿𝗲 𝗮𝘁 𝗘𝗦𝗚𝗖𝗧 𝟮𝟬𝟮𝟰! 🎉 Come visit us at Booth 14/16 to meet the ReiThera team in person! We’re excited to connect with professionals from across the gene and cell therapy space and share insights about our latest innovations. Our collaboration with Virica Biotech will be presented on Thursday 24th at 11AM.

👍👍👍👍👍

🚀 𝗖𝗼𝘂𝗻𝘁𝗶𝗻𝗴 𝗱𝗼𝘄𝗻 𝘁𝗼 𝗘𝗦𝗚𝗖𝗧 𝟮𝟬𝟮𝟰 – 𝗢𝗻𝗹𝘆 𝟮 𝗱𝗮𝘆𝘀 𝘁𝗼 𝗴𝗼! 🚀 Meet us at Booth B14/16 to connect directly with our leadership team: 👨💼 𝗦𝘁𝗲𝗳𝗮𝗻𝗼 𝗖𝗼𝗹𝗹𝗼𝗰𝗮, 𝗖𝗘𝗢 𝗼𝗳 𝗥𝗲𝗶𝗧𝗵𝗲𝗿𝗮 👨💼 𝗖𝗹𝗮𝘂𝗱𝗶𝗼 𝗣𝗮𝗻𝘇𝗮𝗿𝗲𝗹𝗹𝗮, 𝗛𝗲𝗮𝗱 𝗼𝗳 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 Don't miss this opportunity to discuss the latest innovations in gene and cell therapy and explore how ReiThera can collaborate with your team. Book an appointment with us today! 📧 Contact us at: claudio.panzarella@reithera.com businessdevelopment@reithera.com Looking forward to seeing you there! 🙌 #ESGCT2024 #GeneTherapy #CellTherapy #Biotech #Innovation #ReiThera #BusinessDevelopment